Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supply Agreements In Brief

This article was originally published in The Gray Sheet

Executive Summary

Tyco Indermil: Group purchasing organization Consorta awards 50-month dual-source contract to Tyco/U.S. Surgical for Indermil tissue adhesive. Indermil (n-butyl-2-cyanoacrylate), indicated for closure of topical incisions, including laparoscopic incisions and trauma-induced lacerations in areas of low skin tension, will be distributed to Consorta's membership of roughly 300 emergency departments and 400 surgical sites treating minor skin wounds and performing laparoscopic procedures. Tyco/U.S. Surgical exclusively distributes Indermil for manufacturer Henkel Loctite (1"The Gray Sheet" Sept. 16, 2002, p. 20)...

You may also be interested in...

Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19

2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.

Hikma Adds Sesen’s Vicineum To MENA Brands

Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.

Netherlands’ Norgine Sets Up OTC Business And Targets Acquisitions

By establishing a dedicated consumer healthcare subsidiary, Norgine is hoping it can grow its $200m-plus Movicol laxative brand and take advantage of M&A opportunities in the OTC market.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts